-
Authoritative interpretation of the 2022 new guide to hyperthyroidism
Time of Update: 2022-11-04
Jing LiDepartment of Endocrinology, The First Affiliated Hospital of China Medical UniversityProfessor Li Jing pointed out: "It should be noted that non-thyroid TSH reduction must be excluded in the diagnosis process, heterophilic TSH antibody interference, high-dose use of glucocorticoids, mental anxiety and other factors may have non-thyroid TSH level reduction, therefore, the diagnosis of subclinical thyrotoxicosis must be differentiated.
-
What is the efficacy of CD20 CAR-T as a salvage therapy for relapsed/refractory B-NHL with rituximab
Time of Update: 2022-11-01
Study results 01 Baseline characteristics of patientsA total of 15 patients with a median age of 48 years were included, of whom 9 (60%) had relapse and 6 (40%) were refractory to rituximab-based chemotherapy.
Poke "Read Original" to see moreThis study shows that CD20 CAR-T cells are feasible and effective in patients with rituximab-R/R CD20+B-NHL.
-
【WCLC】Broken cocoon and turned into a butterfly and reborn | Amivantamab combined with Lazertinib in the first-line treatment of patients with EGFR-sensitive mutation PFS may exceed 28 months
Time of Update: 2022-08-20
At present, the researchers are conducting a large-scale phase III study MARIPOSA to compare the efficacy and safety of the Amivantamab + Lazertinib regimen and the first-line treatment of osimertinib in patients with EGFR-sensitive mutated NSCLC, which is worth looking forward to .
-
Key points of anesthesia management for cesarean section under general anesthesia
Time of Update: 2022-04-30
Prepare for difficult airway intubation .
D. Intubation is optional for rapid sequential induction .
G. Use rapid sequential induction: intravenous propofol 1.
Maternal muscle relaxants receiving magnesium sulfate treatment should be appropriately reduced .
-
Front Oncol: Domestic multi-center evaluation of the efficacy of Regorafenib (regorafenib) third-line or above in the treatment of patients with refractory metastatic colorectal cancer (mCRC
Time of Update: 2022-04-24
The study included patients with refractory metastatic colorectal cancer (mCRC) from 4 centers in China between February 1, 2018 and June 31, 2021, divided into 3 groups: regorafenib monotherapy, regorafenib Combined chemotherapy group and regorafenib combined with anti-PD-1 treatment group .
-
AJOG: The physiological subtypes of pregnancy glucose intolerance and the risk of adverse pregnancy outcomes
Time of Update: 2021-10-20
After adjusting for age, race and ethnicity, marital status, and body mass index, we used Logistic regression to compare the adverse outcomes of each subtype (gestational age, birth weight, admission to the neonatal intensive care unit, pregnancy-induced hypertension, and autopsy).
-
THALES study subgroup analysis: For stroke patients with arterial stenosis, ticagrelor combined with aspirin may be a better treatment option
Time of Update: 2021-03-27
This exploratory analysis of the THALES study included a total of 2351 patients with ipsilateral stenosis ≥30% with or without aortic arch plaque thickness ≥4 mm, and found that ticagrelor combined with aspirin significantly reduced stroke or The risk of death is 27%, and the NNT is only 34.
-
Venecla combined with ibrutinib in the treatment of relapsed and refractory chronic lymphocytic leukemia: results of phase II VISION study
Time of Update: 2021-03-24
After the 15th cycle of treatment was completed, patients with partial remission (PR) in blood and bone marrow tests and undetectable minimal residual disease (uMRD) were randomly assigned to receive ibrutinib maintenance treatment or watchful waiting.
-
FDA approves for launch of Therapeutics MD's BIJUVA ™ capsule (1 mg/100 mg
Time of Update: 2020-06-11
as the ovaries stop producing hormones and circulating estrogen levels drop, they often develop symptoms of tube aureus (VMS, also known as hot/tidal), as well as sleep and mood disorders and urinar
-
Health care negotiations lead to stock market shocks, ChuanJunshi, Cinda PD-1 has entered health insurance
Time of Update: 2020-06-01
Chuan Junshi, Cinda PD-1 has entered the health insurance on the morning of the 13th, the industry's attention to PD-1 began negotiations Although the results are not yet known, but the industry has
-
Sutro has published the first phase clinical results of its ADC products against ovarian cancer
Time of Update: 2019-10-30
Sutro biopharma, located in San Francisco, California, USA, is a research, development and production enterprise of tumor drugs whose products are in clinical stage The company today released data on
-
Ginkgo biloba extract has no effect on memory
Time of Update: 2010-03-03
Researchers from the University of Pittsburgh reported on December 29, 2009 that taking Ginkgo biloba supplements did not slow down the natural decline of cognitive ability in the elderly The research
